Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 35 papers were listed this time. Here's a couple in our areas of research interest:
The Diabetes Prevention Program Research Group. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention: An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012 Apr;35(4):723-730. PubMed PMID: 22442395.
Zhuo X, Zhang P, Selvin E, et al. Alternative HbA1c Cutoffs to Identify High-Risk Adults for Diabetes Prevention: A Cost-Effectiveness Perspective. Am J Prev Med. 2012 Apr;42(4):374-81. PubMed PMID: 22424250.
Rutten-van Mölken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012 Apr 1;30(4):271-302. PubMed PMID: 22409290.
Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012 Apr;98(7):544-51. Epub 2012 Feb 7. PubMed PMID: 22313548.
